1stOncology™: Cancer Intelligence Service – Page 17057 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Evotec and Boehringer Ingelheim Significantly Expand and Extend their Joint Drug Discovery Collaboration

On January 17, 2006 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") reported that effective from 1 January 2006 Evotec and Boehringer Ingelheim GmbH ("Boehringer") will significantly expand their drug discovery collaboration initiated in September 2004, effectively doubling the already sizeable programme (Press release, Evotec, JAN 17, 2006, View Source;announcements/press-releases/p/evotec-and-boehringer-ingelheim-significantly-expand-and-extend-their-joint-drug-discovery-collaboration-4531 [SID1234538894]). At the same time, the collaboration that was originally projected to end in August 2007 was extended to the end of 2008.

Evotec and Boehringer aim to jointly identify and develop pre-clinical development candidates suitable for future selection as drug candidates for clinical testing. While the original contract was exclusively targeted at therapeutics acting on G-Protein Coupled Receptors (GPCRs), the extension also includes targets from different target classes, including ion channels and enzymes. Boehringer will have the ownership and global responsibility for all clinical development activities, manufacture and commercialisation of the compounds identified in the collaboration.

As compensation for Evotec’s contributions to the programme, Evotec receives ongoing research payments from Boehringer. In addition, Boehringer will pay to Evotec pre-clinical and clinical milestones as well as royalties on drugs discovered in the collaboration. The first project milestone was successfully announced in June 2005, less than one year after the start of this partnership.

Professor Mikael Dolsten, Head of Corporation Division Pharma Research/Discovery, Boehringer Ingelheim GmbH, said: "We are very pleased with the progress we have achieved in our collaboration with Evotec to date. We appreciate the drug discovery performance with the first milestone achieved as well as the positive spirit in the team. This has led us to extend and expand our relationship further."

Joern Aldag, President and Chief Executive Officer at Evotec, said: "Following an extremely successful start to our collaboration we are delighted with Boehringer’s commitment not only to place additional contracts with us but also in having the confidence and trust to significantly expand our drug discovery partnership and broaden it into other target areas. Bringing together our complementary strengths and expertise in one team we have established a powerful platform for the discovery of promising new medicines. As a long-term strategic partner we are proud to have delivered valuable contributions to Boehringer’s research in just a short period of time and look forward to a continued successful collaboration."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, [email protected]
Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, [email protected]

Phogen enters into a Technology Commercialisation Agreement with CRT

On August 1, 2005 Phogen Ltd ("Phogen") and Cancer Research Technology Limited (CRT) reported that they have entered into an exclusive Technology Commercialisation Agreement for the commercialisation of Phogen’s VP22 technology (Press release, Cancer Research Technology, AUG 1, 2005, View Source [SID1234523435]).

Under the terms of the agreement, CRT has agreed to provide Phogen with its expertise to commercialise Phogen’s VP22 Intellectual Property by identifying potential commercial partners and negotiating commercial terms with those parties, including licence agreements and sponsored research collaborations. Financial terms were not disclosed.

VP22 is a versatile platform technology, having utility in its DNA form for enhancing DNA vaccines and gene therapies, while the protein form, denoted Vectosomes, offers multiple delivery applications, which have been demonstrated for candidate therapeutic nucleic-acid based drugs as well as therapeutic proteins.

Dr Peter O’Hare, Phogen’s Co-founder and Director of the Marie Curie Research Institute, commented: "CRT was instrumental in the establishment of Phogen and we are delighted to have signed this agreement with them. It is particularly gratifying that their expertise will be brought to bear in the commercialisation of our technology."

Dr Keith Blundy, Chief Operating Officer of CRT, commented: "This agreement highlights CRT’s expertise and track record in technology commercialisation. We are very pleased to be working with Phogen, a joint venture established by Marie Curie Cancer Care, one of our academic partners."

Evotec OAI Achieves First Milestone in Partnership with Boehringer Ingelheim

On June 7, 2005 Boehringer Ingelheim and Evotec OAI (Frankfurt Stock Exchange: EVT, TecDAX 30) reported on selected G-Protein Coupled Receptors (GPCRs) the first project milestone has been successfully achieved (Press release, Evotec, JUN 7, 2005 View Source;announcements/press-releases/p/evotec-oai-achieves-first-milestone-in-partnership-with-boehringer-ingelheim-4546 [SID1234538884]). Under the terms of the drug discovery collaboration, Evotec OAI AG has received a first research milestone payment from Boehringer Ingelheim. The payment was granted for the identification of a number of lead series for a priority target of this collaboration. Further projects within the multi-target collaboration are progressing on schedule. Evotec OAI is entitled to additional payments from Boehringer Ingelheim based on the achievement of further milestones. Further financial details of the payment were not disclosed.

Dr Mark Ashton, Executive Vice President Business Development Services at Evotec OAI, commented: "We are extremely proud that we have reached our first project milestone with Boehringer Ingelheim in such a short period of time. Over the past nine months we have built an excellent relationship and we are looking forward to a continued fruitful collaboration."

Professor Mikael Dolsten, Head of Corporate Division Pharma Research/Discovery, Boehringer Ingelheim GmbH, said: "We are very pleased with the progress achieved in the collaboration on GPCR targets, which constitute one of the most proven drug target classes in the medical area. Generation of novel leads against a disease relevant GPCR target was successfully achieved in a short time period. The basis for this first milestone achievement was both the excellent drug discovery performance and the good collaboration spirit between the Boehringer Ingelheim and Evotec scientists. We anticipate valuable results from this collaboration."

Contacts:
Evotec OAI AG, Anne Hennecke, Investor Relations & Corporate Communications, 22525 Hamburg, Phone: +49 – 40 – 56081 286 / Boehringer Ingelheim GmbH, Ute Schmidt, Corporate Division Communications, 55216 Ingelheim, Phone: +49 – 6132 – 77 97296
Contacts:

Evotec OAI AG, Anne Hennecke, Investor Relations & Corporate Communications, 22525 Hamburg, Phone: +49 – 40 – 56081 286 / Boehringer Ingelheim GmbH, Ute Schmidt, Corporate Division Communications, 55216 Ingelheim, Phone: +49 – 6132 – 77 97296

CRT announces the appointment of Dr Phil L’Huillier as Director of Business Management

On May 5, 2005 Cancer Research Technology Limited (CRT) is pleased to report the appointment of Dr Phil L’Huillier as Director of Business Management (Press release, Cancer Research Technology, MAY 10, 2005, View Source [SID1234523436]). Previously, Dr L’Huillier was Director of Global Licensing and Business Development at BioFocus Discovery, a UK listed drug discovery company. Prior to BioFocus, Phil headed ProBio Inc, a US specialty IP commercialisation company, involved in international licensing and partnering in the pharmaceutical, genomics and agbiotech sectors (now part of the Pharming Group NV).

The post of Director of Business Management is a new position within CRT, demanded in part by CRT’s ambitious future plans. These include the expansion of CRT’s oncology focused development laboratory enabling CRT to take early-stage projects further downstream, and growing the development services within Europe as well as entry into the US. Dr Keith Blundy, CRT’s Chief Operating Officer stated: "We are delighted to welcome Phil to CRT. CRT’s Business Management Team and indeed the organisation as a whole will benefit greatly from Phil’s guidance and expertise."

Bioheng Therapeutics Announces FDA Clearance of IND Application for CD7 UCAR T Cell Therapy in T-ALL/LBL

On March 5, 2025 Bioheng Therapeutics US LLC ("Bioheng"), a clinical-stage biotech company dedicated to developing innovative universal CAR-T cell therapies, reported that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for CTD402, a CD7-targeted universal CAR-T (UCAR-T) cell therapy, for the treatment of pediatric and adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL) (Press release, Bioheng Biotech, MAR 5, 2005, View Source [SID1234650921]). The study approved by the FDA is a single-arm, open-label Phase Ib/II trial with a simplified dose-finding design, designed to optimize dosing and accelerate clinical development.

"We are delighted that CTD402 has received IND clearance from the U.S. FDA for a Phase Ib/II trial with a simplified dose-finding design, accelerating our clinical development timeline in the United States," stated Jiangtao Ren, Ph.D., President & Chief Scientific Officer (CSO) of Bioheng. "IIT study results showed an impressive ORR, alongside a favorable safety profile. These results validate our ANSWER platform’s ability to deliver both rapid therapeutic impact and reduced patient risk, positioning CTD402 as a potential best-in-class therapy for T-cell malignancies."

About CTD402
CTD402 is a universal CAR-T cell product targeting CD7 derived from healthy donors and intended for the treatment of T-ALL/LBL. It is genetically modified to avoid fratricide, graft-versus-host disease (GvHD), and host-versus-graft rejection (HvG) while enhancing anti-tumor activity. CTD402 can be prepared in a single batch for multiple people, achieving an "off-the-shelf" capability for patients in need of CAR-T cell therapy.

About T-ALL/LBL
T-ALL/LBL are distinct clinical presentations of the same malignancy, originating from immature T-cell lineage lymphoid cells and classified based on the degree of bone marrow involvement. [1] While frontline therapy achieves high complete remission (CR) rates, the majority of patients ultimately experience relapse. Relapsed or refractory (R/R) disease is associated with poor outcomes, with a 5-year overall survival (OS) rate of less than 20%.[2]